These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 35212277)

  • 21. Retrospective Analysis of the Efficacy of Dapagliflozin in Patients with Type 2 Diabetes in a Primary Clinic in Korea.
    Park SH; Choi YJ; Rhee EJ; Huh KB
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):70-79. PubMed ID: 30912340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH; Kim B; Choi H; Kim DJ; Kim HC
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin.
    Kim HS; Shin JA; Lee SH; Kim ES; Cho JH; Son HY; Yoon KH
    Diabetes Technol Ther; 2013 Oct; 15(10):810-6. PubMed ID: 24050737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
    Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relationship between the efficacy of oral antidiabetic drugs and clinical features in type 2 diabetic patients (JDDM38).
    Kanatsuka A; Sato Y; Kawai K; Hirao K; Kobayashi M; Kashiwagi A; ; Abe N; Arai K; Fujiya H; Fukumoto Y; Dake F; Iizumi T; Ito M; Iwasaki K; Kanamori A; Kato S; Kato M; Kawara A; Kimura K; Chikamori K; Iemitsu K; Kou S; Kudo M; Kurihara Y; Lee G; Tsuruoka A; Manda N; Matoba K; Hayashi H; Minami M; Kuribayashi N; Miyazawa K; Chiba Y; Osonoi T; Nakamura S; Sasaki H; Komori K; Oishi M; Okada A; Okuguchi F; Yanagisawa M; Sugimoto H; Sugiyama H; Takai M; Takaki M; Takamura H; Takeda H; Takeda H; Tanaka K; Miwa T; Tomonaga O; Taguchi M; Yamazaki K; Wada T; Yagi N; Yamaoka K; Yuhara A
    J Diabetes Investig; 2016 May; 7(3):386-95. PubMed ID: 27330726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis.
    Rathmann W; Kostev K; Gruenberger JB; Dworak M; Bader G; Giani G
    Diabetes Obes Metab; 2013 Jan; 15(1):55-61. PubMed ID: 22862879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment Patterns of Type 2 Diabetes Assessed Using a Common Data Model Based on Electronic Health Records of 2000-2019.
    Lee KA; Jin HY; Kim YJ; Im YJ; Kim EY; Park TS
    J Korean Med Sci; 2021 Sep; 36(36):e230. PubMed ID: 34519186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH; Feng ZK; Xu LH
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):588-594. PubMed ID: 28789492
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.
    Liu SC; Chien KL; Wang CH; Chen WC; Leung CH
    Endocr Pract; 2013; 19(6):980-8. PubMed ID: 23807528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-Dose Sulfonylurea Plus DPP4 Inhibitor Lower Blood Glucose and Enhance Beta-Cell Function Without Hypoglycemia.
    Cordiner RLM; Bedair K; Mari A; Pearson E
    J Clin Endocrinol Metab; 2024 Jul; 109(8):2106-2115. PubMed ID: 38267622
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors Associated with Type 2 Diabetes Mellitus Treatment Choice Across Four European Countries.
    Heintjes EM; Overbeek JA; Hall GC; Prieto-Alhambra D; Lapi F; Hammar N; Bezemer ID
    Clin Ther; 2017 Nov; 39(11):2296-2310.e14. PubMed ID: 29108837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
    PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Arvay L; Liu D; Patel S; von Eynatten M; Woerle HJ
    Clin Ther; 2012 Sep; 34(9):1909-19.e15. PubMed ID: 22939034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
    White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
    Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea.
    Lukashevich V; Del Prato S; Araga M; Kothny W
    Diabetes Obes Metab; 2014 May; 16(5):403-9. PubMed ID: 24199686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
    Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
    Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults.
    Zullo AR; Smith RJ; Gutman R; Kohler B; Duprey MS; Berry SD; Munshi MN; Dore DD
    J Am Geriatr Soc; 2021 Oct; 69(10):2923-2930. PubMed ID: 34291453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.